• Safi Bello

J&J, Bayer face first jury trial over blockbuster Xarelto's bleeding risks

Fierce Pharma ------ The first federal trial over the bleeding risks of Xarelto, Johnson & Johnson and Bayer’s blockbuster anticoagulant, kicks off next week, with 18,000 more cases stacked up behind it. It will be the initial indicator of whether juries are likely to side with the drugmakers, ruling that their med is safe and effective, or patients, who claim the two companies hid the real risks of the blood thinner. The case in New Orleans was brought by Joseph Boudreaux, who took the drug to cut his stroke risk but claims it caused internal bleeding that caused heart problems and resulted in a visit to intensive care unit for a week, the Chicago Tribune reported. To learn more click on the picture below to read the article.

J&J, Bayer face first jury trial over blockbuster Xarelto's bleeding risks - Read More from Fierce Pharma

1 view
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon